Evidence map›Paper›PMID 35805975›Full record

ArticleInternational journal of molecular sciences2022

Major Histocompatibility Complex Class I Chain-Related α (MICA) STR Polymorphisms in COVID-19 Patients.

Juan Francisco Gutiérrez-Bautista, Alba Martinez-Chamorro, Antonio Rodriguez-Nicolas, Antonio Rosales-Castillo, Pilar Jiménez, Per Anderson, Miguel Ángel López-Ruz, Miguel Ángel López-Nevot, Francisco Ruiz-Cabello

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Investigation ofInternational journal of molecular sciences · 2025
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Juan Francisco Gutiérrez-BautistaServicio de Análisis Clínicos e Inmunología, Hospital Universitario Virgen de las Nieves, 18012 Granada, Spain.
Alba Martinez-ChamorroServicio de Análisis Clínicos, Hospital Universitario de Jaén, 23007 Jaén, Spain.
Antonio Rodriguez-NicolasServicio de Análisis Clínicos e Inmunología, Hospital Universitario Virgen de las Nieves, 18012 Granada, Spain.
Antonio Rosales-CastilloServicio de Medicina Interna, Hospital Universitario Virgen de las Nieves, 18012 Granada, Spain.
Pilar JiménezServicio de Análisis Clínicos e Inmunología, Hospital Universitario Virgen de las Nieves, 18012 Granada, Spain.
Per AndersonServicio de Análisis Clínicos e Inmunología, Hospital Universitario Virgen de las Nieves, 18012 Granada, Spain.
Miguel Ángel López-RuzDepartamento de Medicina, University of Granada, 18071 Granada, Spain.ORCID 0000-0002-1671-4281
Miguel Ángel López-NevotServicio de Análisis Clínicos e Inmunología, Hospital Universitario Virgen de las Nieves, 18012 Granada, Spain.ORCID 0000-0002-3465-6062
Francisco Ruiz-CabelloServicio de Análisis Clínicos e Inmunología, Hospital Universitario Virgen de las Nieves, 18012 Granada, Spain.ORCID 0000-0002-2247-3293
Universidad de Granada · ESHospital Universitario Virgen de las Nieves · ESComplejo Hospitalario de Jaén · ESInstituto de Investigación Biosanitaria de Granada · ES

Funding

Instituto de Salud Carlos III PI 16/00752Regional Government of Andalusia B-CTS-410-UGR-20
6 · The paper itself

Abstract

The SARS-CoV-2 disease presents different phenotypes of severity. Comorbidities, age, and being overweight are well established risk factors for severe disease. However, innate immunity plays a key role in the early control of viral infections and may condition the gravity of COVID-19. Natural Killer (NK) cells are part of innate immunity and are important in the control of virus infection by killing infected cells and participating in the development of adaptive immunity. Therefore, we studied the short tandem repeat (STR) transmembrane polymorphisms of the major histocompatibility complex class I chain-related A (MICA), an NKG2D ligand that induces activation of NK cells, among other cells. We compared the alleles and genotypes of MICA in COVID-19 patients versus healthy controls and analyzed their relation to disease severity. Our results indicate that the MICA*A9 allele is related to infection as well as to symptomatic disease but not to severe disease. The MICA*A9 allele may be a risk factor for SARS-CoV-2 infection and symptomatic disease.

Indexed as

COVID-19Histocompatibility Antigens Class IHumansMajor Histocompatibility ComplexPolymorphism, GeneticSARS-CoV-2Histocompatibility Antigens Class IMHC class I-related chain Ainnate immunityMICAMICA STR polymorphismsNK cellsSARS-CoV-2

Identifiers

PMID35805975
PMCPMC9266713
OpenAlexW4283391133

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.